A Cross-Domain Enterprise LIMS Architecture for Organ Bioprinting: Bridging R&D, Process Development, QC, and GMP Manufacturing

Title

A Cross-Domain Enterprise LIMS Architecture for Organ Bioprinting: Bridging R&D, Process Development, QC, and GMP Manufacturing

Author

1. Niranjana Raghunathan, Scientist, GSK, United States

Abstract

Organ-scale three-dimensional (3D) bioprinting is poised to transform transplantation medicine and advanced therapeutics; however, translation from laboratory innovation to regulated, multi-site manufacturing remains constrained by fragmentation across research (R&D), process development (PD), quality control (QC), and GMP production. This paper presents a cross-domain enterprise systems architecture that positions Laboratory Information Management Systems (LIMS) as the digital backbone spanning discovery through commercial manufacturing, establishing a continuous, auditable digital thread for organ bioprinting. We define quantitative manufacturing and translation metrics Reproducibility Index (RI), Throughput Scalability Factor (TSF), Protocol Deviation Rate (PDR), and Documentation Completeness Score (DCS) and a validation-by-design lifecycle aligned to GAMP5. The framework is grounded in thirteen years of enterprise-scale LIMS and data-integrity leadership across pharmaceutical R&D, QC, and manufacturing. This paper follows the SCIRP structure and proposes a systems engineering framework integrating LIMS into bioprinting. We argue that organ bioprinting will not become an industrial discipline without cross-domain informatics governance, and we provide an immediately actionable blueprint for implementation.

Keywords

Conclusion

This work argues that the principal barrier to the industrialization of organ bioprinting is not the pace of biological or materials innovation, but the absence of manufacturing-grade digital governance, data continuity, and lifecycle control. Through the synthesis of lessons from regulated pharmaceutical manufacturing and the formulation of a cross-domain architectural framework, we show how a LIMS-centered digital backbone can provide the missing translational infrastructure linking discovery, development, quality, and production into a single, coherent system.

By defining a unified digital thread spanning materials, processes, equipment, and quality decisions, the proposed architecture transforms bio fabrication from a collection of isolated experimental workflows into a cyber-physical manufacturing platform. The accompanying quantitative framework establishes, for the first time, a set of cross-domain metrics reproducibility, scalability, execution discipline, and documentation completeness that allow progress in bio fabrication to be evaluated not only by construct performance, but by manufacturing readiness and system maturity.

Although the numerical results presented here are necessarily projected, their magnitude and direction are consistent with decades of experience in regulated life sciences manufacturing. This strongly suggests that the same architectural principles can enable organ bioprinting to traverse the critical transition from laboratory demonstrations to reliable, inspectable, multi-site production systems.

More broadly, the framework outlined in this work provides a foundation for distributed, resilient bio fabrication manufacturing networks, in which innovation, scale-up, and production can proceed in parallel under a shared digital and quality governance model. Such an infrastructure is not merely an enabler of scientific translation; it is a prerequisite for transforming organ bioprinting into a dependable component of modern healthcare systems.

In this sense, the central contribution of this work is not specific software architecture, but a reframing of bio fabrication itself: from an instrument-centered experimental practice into a manufacturing discipline governed by systems engineering principles. It is this shift rather than any single technological breakthrough that will ultimately determine whether organ bioprinting achieves durable clinical and societal impact.

Author Contrubution

Niranjana Raghunathan conceived the study, developed the architectural framework and quantitative methodology, performed the literature analysis and systems synthesis, and wrote the manuscript.

Funding

This research received no external funding.

Conflict of Interest

The authors declare no conflicts of interest regarding the publication of this pa-per.

Data Sharing Statement

No clinical trials or human subject studies were conducted as part of this work. The study is based on publicly available literature and de-identified, aggregated industrial reference data that cannot be shared due to confidentiality and contractual restrictions. All conceptual frameworks, metric definitions, and methodological descriptions necessary to reproduce the analytical approach are provided within the article.

Software And Tools Use

Acknowledgements

Avoid the stilted expression, “One of us (R. B. G.) thanks...” Instead, try “R. B. G. thanks”. Do NOT put sponsor acknowledgements in the unnumbered footnote on the first page, but at here.